Compare Cigna Corp (CI) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Cigna Corp trades at $272.72 (market cap $73.56B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $11.05. The key difference: Cigna Corp pays a 2.24% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none, and Cigna Corp is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| CI | MSTZ | |
|---|---|---|
Market Cap | $73.56B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $311.00 | $27.92 |
52-Week Low | $244.41 | $3.88 |
Enterprise Value | $98.27B | — |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.
The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.
MSTZ's stock is currently trading at $10.3, down 6.19% over the past 24 hours, reflecting significant bearish pressure. Technical indicators are predominantly bearish, with moving averages signaling a downtrend and key support levels identified near $9 and $8. The absence of reported financial ratios such as P/E and P/S limits fundamental clarity, while recent news highlights ETF performance unrelated to the company's core business, indicating a lack of direct catalysts.
The outlook for MSTZ appears cautious due to weak technical momentum and limited fundamental visibility. Investment opportunities are constrained by the bearish signal and absence of recent financial data, posing risks from market volatility and potential competitive pressures. Investors should seek updated earnings reports for a clearer assessment of the company's financial health and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
